Recevez les dernières nouvelles sur l'action CRISPR Therapeutics avec des mises à jour sur les tendances du marché, les données financières et les analyses de Benzinga. Restez informé des performances de CRSP

Dernières nouvelles pour

CRISPR Therapeutics

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

CRISPR Therapeutics AG

Earnings

Press Releases

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

Health Care

General

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies

News

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Four Rising Stars Driving the Next Wave of Stem Cell and Gene Therapy Innovation

CRISPR Therapeutics Named to TIME's Most Influential Companies List of 2025

Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth

Small Cap

Opinion

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

ADIA

CLDI

CRSP

CTMX

FATE

IBRX

LCTX

MESO

VRTX

Abivax

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Alkermes

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Jyong Biotech

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Merus

Metsera

Nuvalent

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

TG Therapeutics

HC Wainwright & Co.

Barclays

Chardan Capital

RBC Capital

B of A Securities

Comments

CRISPR Therapeutics Actualités boursières

Actualités

Dernières nouvelles pour

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL